Below are the most recent publications written about "Hemagglutination Inhibition Tests" by people in Profiles.
-
Claeys C, Chandrasekaran V, Garc?a-Sicilia J, Prymula R, D?ez-Domingo J, Brzostek J, Mar?s-Berm?dez J, Martin?n-Torres F, Pollard AJ, Ru?kov? R, Carmona Martinez A, Ulied A, Miranda Valdivieso M, Faust SN, Snape MD, Friel D, Ollinger T, Soni J, Schuind A, Li P, Innis BL, Jain VK. Anamnestic Immune Response and Safety of an Inactivated Quadrivalent Influenza Vaccine in Primed Versus Vaccine-Na?ve Children. Pediatr Infect Dis J. 2019 02; 38(2):203-210.
-
Claeys C, Drame M, Garc?a-Sicilia J, Zaman K, Carmona A, Tran PM, Miranda M, Martin?n-Torres F, Thollot F, Horn M, Schwarz TF, Behre U, Merino JM, Sadowska-Krawczenko I, Szymanski H, Schu P, Neumeier E, Li P, Jain VK, Innis BL. Assessment of an optimized manufacturing process for inactivated quadrivalent influenza vaccine: a phase III, randomized, double-blind, safety and immunogenicity study in children and adults. BMC Infect Dis. 2018 04 18; 18(1):186.
-
Ofori-Anyinam O, Leroux-Roels G, Drame M, Aerssens A, Maes C, Amanullah A, Schuind A, Li P, Jain VK, Innis BL. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine versus separate administration, in adults =50years of age: Results from a phase III, randomized, non-inferiority trial. Vaccine. 2017 11 01; 35(46):6321-6328.
-
Kandeil A, Mostafa A, El-Shesheny R, El-Taweel AN, Gomaa M, Galal H, Kayali G, Ali MA. Avian influenza H5N1 vaccination efficacy in Egyptian backyard poultry. Vaccine. 2017 10 27; 35(45):6195-6201.
-
Zerbini CA, Ribeiro Dos Santos R, Jose Nunes M, Soni J, Li P, Jain VK, Ofori-Anyinam O. Immunogenicity and safety of Southern Hemisphere inactivated quadrivalent influenza vaccine: a Phase III, open-label study of adults in Brazil. Braz J Infect Dis. 2017 Jan - Feb; 21(1):63-70.
-
Hakim H, Allison KJ, Van de Velde LA, Tang L, Sun Y, Flynn PM, McCullers JA. Immunogenicity and safety of high-dose trivalent inactivated influenza vaccine compared to standard-dose vaccine in children and young adults with cancer or HIV infection. Vaccine. 2016 06 08; 34(27):3141-3148.
-
Wang L, Chandrasekaran V, Domachowske JB, Li P, Innis BL, Jain VK. Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine in US Children 6-35 Months of Age During 2013-2014: Results From A Phase II Randomized Trial. J Pediatric Infect Dis Soc. 2016 Jun; 5(2):170-9.
-
Curtis DJ, Muresan P, Nachman S, Fenton T, Richardson KM, Dominguez T, Flynn PM, Spector SA, Cunningham CK, Bloom A, Weinberg A. Characterization of functional antibody and memory B-cell responses to pH1N1 monovalent vaccine in HIV-infected children and youth. PLoS One. 2015; 10(3):e0118567.
-
Rodriguez Weber MA, Claeys C, Aranza Doniz C, Feng Y, Innis BL, Jain VK, Peeters M. Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18-47 months of age. Pediatr Infect Dis J. 2014 Dec; 33(12):1262-9.
-
Tinoco JC, Pavia-Ruz N, Cruz-Valdez A, Aranza Doniz C, Chandrasekaran V, Dew? W, Liu A, Innis BL, Jain VK. Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged =18 years: a phase III, randomized trial. Vaccine. 2014 Mar 14; 32(13):1480-7.